行业观察 | 国内唯一获批干细胞药品开出首张处方,价格仅为美国同类药物的1/70

财经大健康
17 Jun

获批上市,对于一款创新药物来说,是一个里程碑,获批之后的临床应用、数据追溯、患者健康管理等,是药物商业化成功的关键2025年6月5日,国内唯一获批上市的干细胞药物艾米迈托赛注射液(睿铂生)首张处方,在北京大学人民医院由黄晓军院士团队开出,用于治疗一位激素治疗失败的急性移植物抗宿主病(aGVHD)患者。艾米迈托赛注射液由铂生卓越生物科技(北京)有限公司(下称“铂生生物”)自主研发。1月2日,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10